BLK vs DHR: Which Is the Better Buy?

Side-by-side comparison of BlackRock, Inc. and Danaher Corporation β€” fair value, conviction, valuation metrics, and QuantHub research signals. Updated 2026-07-15.
BlackRock, Inc. Β· Financial Services
$1,025.44
+31.0% upside to fair value
Grade A High Quality
VS
Danaher Corporation Β· Healthcare
$195.98
+7.9% upside to fair value
Grade B High Quality
QuantHub Verdict
BLK has more upside to fair value (+31.0%). BLK trades at a lower forward P/E (24.2x). These are model outputs β€” not personalized investment advice. See all research β†’
Valuation & Fundamentals
Metric BLK DHR
Current Price $1,025.44 $195.98
Fair Value Estimate $1,343.02 $211.54
Upside to Fair Value +31.0% +7.9%
Market Cap $158.9B $138.7B
Forward P/E 24.2x 37.8x
EV / EBITDA 16.0x 22.8x
Price / Sales 5.8x 5.6x
Price / FCF 44.6x 26.2x
Revenue Growth YoY +30.6% +3.7%
Gross Margin 54.6% 60.7%
Operating Margin 32.9% 21.0%
Return on Equity 12.5% 7.1%
Dividend Yield 0% 0%
FCF Yield 2.24% 3.81%
Analyst Consensus Strong Buy Strong Buy
Investment Thesis
BLK β€” BlackRock, Inc.
BlackRock, Inc. is a leading global asset management firm operating within the financial services sector, specializing in investment management and risk advisory. The company demonstrates high business quality with a durable competitive moat supported by strong brand recognition, intangible assets, and switching costs. It reported robust growth in the most recent quarter with revenue up 30.6% yea…
DHR β€” Danaher Corporation
Danaher Corporation operates in the healthcare sector, specifically in medical diagnostics and research, delivering high-quality products with a durable competitive moat supported by strong margins and consistent earnings growth. The company trades at a trailing and forward P/E of 37.76, which is relatively high but justified by its stable revenue growth of 3.7% and earnings growth of 7.9% in the…
Accumulation Zones
Metric BLK DHR
Zone Low $1,007.26 $158.66
Zone High $1,141.57 $179.81
In Buy Zone? Yes No
← BLK Research    DHR Research β†’    All Research